https://orcid.org/0000-0002-0976-5478
Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Alberto Ortiz, Roberto Alcázar Arroyo, Pedro Pablo Casado Escribano, Beatriz Fernández-Fernández, Francisco Martínez Debén, Juan Diego Mediavilla, Alfredo Michan-Doña, Maria Jose Soler & Jose Luis Gorriz. (2023) Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone. Expert Review of Clinical Pharmacology 16:6, pages 519-531.
Read now
Read now
Articles from other publishers (11)
Amy K. Mottl & Susanne B. Nicholas. (2024) KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases 83:3, pages 277-287.
Crossref
Crossref
Chang Geng, Yu-Cheng Mao, Su-fen Qi, Kai Song, Hong-Fei Wang, Zi-yan Zhang & Qing-Bao Tian. (2023) Mineralocorticoid receptor antagonists for chronic heart failure: a meta-analysis focusing on the number needed to treat. Frontiers in Cardiovascular Medicine 10.
Crossref
Crossref
Irina N. Bobkova. (2023) The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review. Terapevticheskii arkhiv 95:9, pages 796-801.
Crossref
Crossref
Hiroshi Bando, Noboru Iwatsuki, Masaki Okada, Tomoya Ogawa & Kazuki Sakamoto. (2023) Maintained Renal Function by Blood Pressure Control in Patient with Diabetic Kidney Disease (DKD). Asploro Journal of Biomedical and Clinical Case Reports 6:2, pages 130-137.
Crossref
Crossref
Luca Di Lullo, Carlo Lavalle, Alessia Scatena, Marco Mariani, Claudio Ronco & Antonio Bellasi. (2023) Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. Journal of Clinical Medicine 12:12, pages 3992.
Crossref
Crossref
Randa Farah, Abdulrahman Alhajahjeh, Amani Nofal, Tala Basheer Hyasat, Raghed Abdel Hay Abu Jabeh, Lojayn Tareq Suboh, Hussam Alhawari, Munther S. Momani, Hazem Jamal Jaber & Izzat AlAwwa. (2023) Clinical outcomes in patients with type 2 diabetes mellitus-related kidney disease: A Jordanian population cohort study. Journal of Diabetes and its Complications 37:6, pages 108478.
Crossref
Crossref
Francesco Piccirillo, Paola Liporace, Annunziata Nusca, Vincenzo Nafisio, Andrea Corlianò, Francesca Magarò, Raffaele Antonelli Incalzi, Gian Paolo Ussia & Francesco Grigioni. (2023) Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review. Journal of Cardiovascular Development and Disease 10:6, pages 236.
Crossref
Crossref
Wujisiguleng Bao, Mingzhu Zhang, Ning Li, Zhi Yao & Luying Sun. (2022) Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. European Journal of Clinical Pharmacology 78:12, pages 1877-1887.
Crossref
Crossref
Makoto Ogi, Takuya Seto & Yoshinori Wakabayashi. (2022) A comparison of the utility of the urine dipstick and urine protein-to-creatinine ratio for predicting microalbuminuria in patients with non-diabetic lifestyle-related diseases -a comparison with diabetes. BMC Nephrology 23:1.
Crossref
Crossref
Yichuan Wu, Huanjia Lin, Yuan Tao, Ying Xu, Jiaqi Chen, Yijie Jia & Zongji Zheng. (2022) Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease. Frontiers in Pharmacology 13.
Crossref
Crossref
Luis D'Marco, Xavier Guerra-Torres, Iris Viejo, Luis Lopez-Romero, Alejandra Yugueros & Valmore Bermúdez. (2022) Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria. European Endocrinology 18:2, pages 102.
Crossref
Crossref